- Home
- OPRA vs GYRE Comparison
OPRA vs GYRE Comparison
Compare OPRA & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPRA
- GYRE
- Stock Information
- Founded
- OPRA 1996
- GYRE 2002
- Country
- OPRA Norway
- GYRE United States
- Employees
- OPRA N/A
- GYRE N/A
- Industry
- OPRA Computer Software: Prepackaged Software
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- OPRA Technology
- GYRE Health Care
- Exchange
- OPRA Nasdaq
- GYRE Nasdaq
- Market Cap
- OPRA 1.6B
- GYRE 1.3B
- IPO Year
- OPRA 2018
- GYRE N/A
- Fundamental
- Price
- OPRA $19.30
- GYRE $11.75
- Analyst Decision
- OPRA Strong Buy
- GYRE
- Analyst Count
- OPRA 4
- GYRE 0
- Target Price
- OPRA $24.75
- GYRE N/A
- AVG Volume (30 Days)
- OPRA 696.6K
- GYRE 61.7K
- Earning Date
- OPRA 10-29-2024
- GYRE 11-13-2024
- Dividend Yield
- OPRA 4.13%
- GYRE N/A
- EPS Growth
- OPRA 142.24
- GYRE N/A
- EPS
- OPRA 1.78
- GYRE N/A
- Revenue
- OPRA $447,818,000.00
- GYRE $105,033,000.00
- Revenue This Year
- OPRA $21.42
- GYRE $25.32
- Revenue Next Year
- OPRA $15.51
- GYRE $12.95
- P/E Ratio
- OPRA $10.96
- GYRE N/A
- Revenue Growth
- OPRA 17.82
- GYRE N/A
- 52 Week Low
- OPRA $10.11
- GYRE $8.26
- 52 Week High
- OPRA $20.00
- GYRE $30.40
- Technical
- Relative Strength Index (RSI)
- OPRA 66.37
- GYRE 34.51
- Support Level
- OPRA $17.77
- GYRE $12.33
- Resistance Level
- OPRA $20.00
- GYRE $13.24
- Average True Range (ATR)
- OPRA 0.75
- GYRE 1.23
- MACD
- OPRA 0.05
- GYRE -0.41
- Stochastic Oscillator
- OPRA 75.78
- GYRE 0.68
About OPRA Opera Limited
Opera Ltd is a world-wide internet brand with a large, engaged and growing base. It offers users products and services that include a variety of PC and mobile browsers, Opera Gaming portals and development tools, Opera News content recommendation products, and a number of e-commerce products and services. Its features include tabbed browsing, data savings, PC/mobile sync, and numerous features focused on privacy and security, including ad blocking and a built-in VPN. Its browser products include Opera Mini, Opera Browser for Android and iOS, Opera for Computers, Opera GX and Opera GX Mobile, separate browsers tailored for gamers. The newest addition of browsers is the beta release of a Web3-centric browser for PC and mobile which is tailored for crypto enthusiasts.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.